Overview of the 2010 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee Meeting Regarding Ticagrelor

被引：37

作者：

Gaglia, Michael A., Jr. ^{[1
]}

Waksman, Ron ^{[1
]}

机构：

[1] Washington Hosp Ctr, Div Cardiol, Washington, DC 20010 USA

来源：

CIRCULATION | 2011年 / 123卷 / 04期

关键词：

Food and Drug Administration; pharmacology; ticagrelor; antiplatelet drugs; ACUTE CORONARY SYNDROMES; ST-SEGMENT ELEVATION; MYOCARDIAL-INFARCTION; ADENOSINE-DIPHOSPHATE; CLOPIDOGREL; ASPIRIN; PRASUGREL; TRIAL; POLYMORPHISMS; INTERVENTION;

D O I：

10.1161/CIRCULATIONAHA.110.985325

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：451 / 456

页数：6

共 23 条

[1]

AstraZeneca, 2010, M CARD REN DRUGS ADV

[2]

Bonello L, 2008, J AM COLL CARDIOL, V51, pA258

[3] Consensus and Future Directions on the Definition of High On-Treatment Platelet Reactivity to Adenosine Diphosphate [J].

Bonello, Laurent ;

Tantry, Udaya S. ;

Marcucci, Rossella ;

Blindt, Ruediger ;

Angiolillo, Dominick J. ;

Becker, Richard ;

Bhatt, Deepak L. ;

Cattaneo, Marco ;

Collet, Jean Philippe ;

Cuisset, Thomas ;

Gachet, Christian ;

Montalescot, Gilles ;

Jennings, Lisa K. ;

Kereiakes, Dean ;

Sibbing, Dirk ;

Trenk, Dietmar ;

Van Werkum, Jochem W. ;

Paganelli, Franck ;

Price, Matthew J. ;

Waksman, Ron ;

Gurbel, Paul A. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2010, 56 (12) :919-933

[4] Safety, tolerability, and initial efficacy of AZD6140, the first reversivle oral adenosine diphosphate receptor antagonist, compared with clopidigrel, in patients with non-ST-segment elevation acute coronary syndrome - Primary results of the DISPERSE-2 trial [J].

Cannon, Christopher P. ;

Husted, Steen ;

Harrington, Robert A. ;

Scirica, Benjamin M. ;

Emanuelsson, Hakan ;

Storey, Robert F. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 50 (19) :1844-1851

[5] Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial [J].

Chen, ZM ;

Jiang, LX ;

Chen, YP ;

Xie, JX ;

Pan, HC ;

Peto, R ;

Collins, R ;

Liu, LS ;

Chen, ZM ;

Liu, LS ;

Collins, R ;

Jiang, LX ;

Chen, YP ;

Xie, JX ;

Pan, HC ;

Peto, R ;

Cai, NS ;

Chen, YZ ;

Cui, JJ ;

Dai, GZ ;

Feng, JZ ;

Fu, SY ;

Gent, M ;

Gong, LS ;

Hu, DY ;

Huang, DJ ;

Huang, J ;

Huang, TG ;

Huang, ZW ;

Hui, RT ;

Jiang, BQ ;

Li, DY ;

Li, SM ;

Li, TD ;

Li, YQ ;

Li, ZQ ;

Liu, YH ;

Meng, QY ;

Qian, TJ ;

San, J ;

Tao, SQ ;

Wang, DW ;

Wang, LH ;

Wang, W ;

Wu, HA ;

Xi, WH ;

Xu, CB ;

Yang, DC ;

Yang, XF ;

Yin, JQ .

LANCET, 2005, 366 (9497) :1607-1621

[6] The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin [J].

Clarke, TA ;

Waskell, LA .

DRUG METABOLISM AND DISPOSITION, 2003, 31 (01) :53-59

[7]

Fiorentino R. P., 2010, NDA 22 433 BRIL TIC

[8]

Gurbel P, 2009, CIRCULATION, V120, pS1143

[9] Response to Ticagrelor in Clopidogrel Nonresponders and Responders and Effect of Switching Therapies The RESPOND Study [J].

Gurbel, Paul A. ;

Bliden, Kevin P. ;

Butler, Kathleen ;

Antonino, Mark J. ;

Wei, Cheryl ;

Teng, Renli ;

Rasmussen, Lars ;

Storey, Robert F. ;

Nielsen, Tonny ;

Eikelboom, John W. ;

Sabe-Affaki, Georges ;

Husted, Steen ;

Kereiakes, Dean J. ;

Henderson, David ;

Patel, Dharmendra V. ;

Tantry, Udaya S. .

CIRCULATION, 2010, 121 (10) :1188-1199

[10] Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis:: a double-blind comparison to clopidogrel with aspirin [J].

Husted, S ;

Emanuelsson, H ;

Heptinstall, S ;

Sandset, PM ;

Wickens, M ;

Peters, G .

EUROPEAN HEART JOURNAL, 2006, 27 (09) :1038-1047

← 1 2 3 →